{"slideshow_credits": null, "snippet": "TPG Capital has agreed to buy the generic drug maker Par Pharmaceutical in a $1.9 billion leveraged buyout, as merger activity in the health care industry continues to heat up.", "abstract": "TPG Capital has agreed to buy the generic drug maker Par Pharmaceutical in a $1.9 billion leveraged buyout, as merger activity in the health care industry continues to heat up.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"lastname": "DE LA MERCED", "rank": 1, "firstname": "Michael", "role": "reported", "organization": "", "middlename": "J."}], "original": "By MICHAEL J. DE LA MERCED"}, "web_url": "http://dealbook.nytimes.com/2012/07/16/tpg-to-buy-par-pharmaceutical-for-1-9-billion/", "lead_paragraph": null, "headline": {"main": "TPG to Buy Par Pharmaceutical for $1.9 Billion", "kicker": "DealBook"}, "_id": "50042ce01c22dfde670b0658", "word_count": "222", "multimedia": [], "pub_date": "2012-07-16T10:56:57Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "Par Pharmaceutical Companies Inc", "rank": "1"}, {"name": "organizations", "value": "TPG Capital", "rank": "2"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}